Eosinophilic Esophagitis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Eosinophilic Esophagitis – Drugs In Development, 2024 report and make more profitable business decisions.
Eosinophilic esophagitis is disease characterized by the presence of a large number of a special type of white blood cell, the eosinophil, that can cause inflammation in the esophagus. Symptoms include poor weight gain, abdominal pain, nausea, and vomiting; coughing; heartburn; and chest pain. Risk factors include weakened immune system, chemotherapy, aspirin and anti-inflammatory medications, chronic vomiting, obesity, and alcohol or cigarette use. Treatment includes antivirals, antifungals, and pain relievers.
The Eosinophilic Esophagitis drugs in development market research report provide comprehensive information on the therapeutics under development for Eosinophilic Esophagitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Eosinophilic Esophagitis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Eosinophilic Esophagitis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 39 molecules, with 39 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Eosinophilic Esophagitis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Eosinophilic Esophagitis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Eosinophilic Esophagitis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Adare Pharma SolutionsAkeso Inc
Amgen Inc
Amytrx Therapeutics Inc
Aqilion AB
Banner Life Sciences LLC
Bioprojet SCR
Bristol-Myers Squibb Co
Calypso Biotech SA
Celldex Therapeutics Inc
Cellix Bio Pvt Ltd
CSL Ltd
Delta 4 GmbH
Dr. Falk Pharma GmbH
Ellodi Pharmaceuticals
EsoCap AG
Eupraxia Pharmaceuticals Inc
GSK plc
Invea Therapeutics Inc
JSR Life Sciences LLC
Kymera Therapeutics Inc
Lanier Biotherapeutics Inc
Lexeo Therapeutics Inc
Morphic Therapeutic Inc
NImmune Biopharma Inc
Palo BioFarma SL
Pantherics Inc
Pfizer Inc
Quorum Innovations LLC
RAPT Therapeutics Inc
Regeneron Pharmaceuticals Inc
Revolo Biotherapeutics Ltd
Serpin Pharma LLC
Suzhou Connect Biopharmaceuticals Ltd
Takeda Pharmaceutical Co Ltd
Ventyx Biosciences Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Eosinophilic Esophagitis reports